Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Non Operating Income (2019 - 2024)

Eton Pharmaceuticals (ETON) has disclosed Non Operating Income for 6 consecutive years, with -$1.1 million as the latest value for Q4 2024.

  • Quarterly Non Operating Income fell 7025.0% to -$1.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Dec 2024, down 340.76% year-over-year, with the annual reading at -$3.7 million for FY2025, 206.69% down from the prior year.
  • Non Operating Income hit -$1.1 million in Q4 2024 for Eton Pharmaceuticals, down from -$8000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $676000.0 in Q2 2023 to a low of -$1.1 million in Q4 2024.
  • Historically, Non Operating Income has averaged -$149900.0 across 5 years, with a median of -$171000.0 in 2020.
  • Biggest five-year swings in Non Operating Income: skyrocketed 410.09% in 2023 and later crashed 7025.0% in 2024.
  • Year by year, Non Operating Income stood at -$267000.0 in 2020, then dropped by 3.0% to -$275000.0 in 2021, then skyrocketed by 45.45% to -$150000.0 in 2022, then surged by 89.33% to -$16000.0 in 2023, then plummeted by 7025.0% to -$1.1 million in 2024.
  • Business Quant data shows Non Operating Income for ETON at -$1.1 million in Q4 2024, -$8000.0 in Q3 2024, and -$52000.0 in Q2 2024.